02.06.2021 • News

Lanxess Closes Sale of Organic Leather Chemicals Unit

Following all approvals, German specialty chemicals producer Lanxess completed the sale of its organic leather chemicals business to TFL Ledertechnik on Jun. 1. The buyer is a global supplier of leather chemicals and a portfolio company of US private equity investor Black Diamond Capital Management.

The deal agreed in August last year includes all operations of the organic leather chemicals business line with around 420 employees. TFLs is paying a fixed sum of €80 million. A second component leverages a trade working capital mechanism that foresees a payment of around EUR 20 million in the 2021 third quarter. Thirdly, the purchase price includes a performance-related component of up to €115 million, to be paid out over the next three years. TFL also is assuming “certain liabilities.”

With the closing, Lanxess is finally exiting the leather chemicals field. In January 2020, it divested its chrome chemicals business and at the end of 2019 agreed to sell its stake in the related South African chrome ore mine. Since the end of 2019, that time, the Cologne-based chemicals and plastics producer has reported the leather business unit as a discontinued operation.

Author: Dede Williams, Freelance Journalist

German specialty chemicals producer Lanxess closed the sale of its organic...
German specialty chemicals producer Lanxess closed the sale of its organic leather chemicals business to TFL Ledertechnik on Jun. 1. The buyer, a global supplier of leather chemicals, is a portfolio company of US private equity investor Black Diamond Capital Management. (c) Lanxess

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read